Curve Therapeutics
PrivateLast Round
Series A
Feb 27, 2024
Total Funding Raised
$62.92M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Curve Therapeutics operates in Healthcare & Life Sciences and is based in Southampton. Its latest recorded funding round was a Series A round in February 2024.
Curve Therapeutics is a biotechnology company that develops a drug discovery platform for creating macrocycle-derived therapeutics to treat cancer, immunology, and inflammation.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Curve Therapeutics Comparables
Compare Curve Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Orbis Medicines | 88% | |
| BRT Biotechnologies | 86% | |
| Insamo | 84% |
For institutional investors. Book with your work email.
Curve Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 27, 2024 | ||||
| Seed | Jul 31, 2020 | ||||
| Seed | Jun 27, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Curve Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Epidarex Capital | Seed, Series A |
| Advent Life Sciences | Series A, Seed |
| British Patient Capital | Series A |
| British Patient Capital | Series A |
| Pfizer Ventures | Series A |
| Pfizer | Series A |
| Columbus Venture Partners | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Monthly visitors increased 225% MoM.
- Jun 25, 2025
Co-Founder recognized with the Interdisciplinary Prize by the Royal Society of Chemistry.
For institutional investors. Book with your work email.
Curve Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Curve Therapeutics's valuation, stock price, and market status.
Is Curve Therapeutics a public or private company?
Curve Therapeutics is a private company.
What is the current stock price of Curve Therapeutics?
Curve Therapeutics is a private company, so its shares have no public market price. Caplight tracks Curve Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Curve Therapeutics worth (valuation)?
Valuation information for Curve Therapeutics is not publicly available.
Can I buy Curve Therapeutics stock?
Curve Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Curve Therapeutics's last funding round?
Curve Therapeutics's most recent funding round was Series A on February 27, 2024.
Who are the main investors in Curve Therapeutics?
Key investors in Curve Therapeutics include Epidarex Capital, Advent Life Sciences, Pfizer Ventures, Pfizer, Columbus Venture Partners.
Will Curve Therapeutics IPO soon?
No public IPO plans have been announced for Curve Therapeutics.
How can I track Curve Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Curve Therapeutics's shares on secondary markets.